Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings GlaxoSmithKline Pharmaceuticals Limited: Strengths and Weaknesses

Highlights: GlaxoSmithKline Pharmaceuticals Limited
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: GlaxoSmithKline Pharmaceuticals Limited
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.99 times its estimated earnings per share for the ongoing year.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The group usually releases earnings worse than estimated.

Rating Financials

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

GlaxoSmithKline Pharmaceuticals Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
529.67Cr - - - -
1,02400Cr
A
66TCr -
BBB
- -
45TCr
AAA
-
35TCr
AA
29TCr
AAA
25TCr
A
24TCr
A
21TCr
BBB
19TCr
AA
Average 36.73TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. GLAXO Stock
  5. Ratings GlaxoSmithKline Pharmaceuticals Limited
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!